A bone drug already on the market for osteoporosis may kill chronic myelogenous leukemia stem cells thought to persist in the bone marrow after standard therapy, lowering the likelihood of disease recurrence, according to a new study in mice led by researchers at Massachusetts General Hospital , the Harvard Stem Cell Institute and the Harvard ... (more)
http://www.biosciencetechnology.com/news/2013/10/evicting-leukemia
http://www.biosciencetechnology.com/news/2013/10/evicting-leukemia
No comments:
Post a Comment